Oral Oncolytics 
Therapy Initiation Resources
- QOPI Measure Core13oc4 – Documented plan for oral chemotherapy (defect-free measure, Core13oc4a-d)
- Core13oc4a – Dose
- Core13oc4b – Administration schedule (start day, days of treatment/rest and planned duration)
- Core13oc4c – Provided to patient/caregiver prior to start of therapy and practitioner(s) providing continuing care (PCP) within 3 months of starting therapy
- Core13oc4d – Indications
- Oral Oncolytic Checklist
- Medication Reconciliation Process Summary
- Oral Oncolytic Initiation Template
- Primary Care Physician Oral Oncolytic Template
- Initial Dose Mailer
- Calendar
Education Resources
- QOPI Measure Core13oc5 – Oral chemotherapy education provided prior to the start of therapy (defect-free measure, Core13oc5a-c)
- Core13oc5a – Missed doses
- Core13oc5b – Toxicities
- Core13oc5c – Clinic contact instructions
Drug Specific Resources
Monitoring Resources
- QOPI Measure Core13oc6 – Oral chemotherapy monitored on visit/contact following start of therapy (defect-free measure, Core13oc6a-b)
- Core13oc6a – Medication adherence assessed
- Core13oc6b – Medication adherence addressed
- Patient Reported Outcome (PRO) Intake Document
- Patient Reported Outcome (PRO) Assessment
- Patient Reported Outcome (PRO) Tool Guide
- Oral Oncolytic Monitoring Note Template
MOQC Oral Oncolytic Publications
- Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM)
- 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard
- Impact of a Statewide Oral Oncolytic Initiative on Five Participating Practices
- Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy
- The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices
- Improving Oral Oncolytic Patient Self-Management
